About Vaxine
Vaxine is a company based in Bedford Park (Australia) founded in 2002.. Vaxine offers products and services including Advax™ Adjuvant Platform, COVID-19 Vaccine, Influenza Vaccine, and Hepatitis B Vaccine. Vaxine operates in a competitive market with competitors including Emergent BioSolutions, EyeGene, Adjuvance Technologies, Kineta and Eikonoklastes, among others.
- Headquarter Bedford Park, Australia
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Vaxine Pty Ltd
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Vaxine
Vaxine offers a comprehensive portfolio of products and services, including Advax™ Adjuvant Platform, COVID-19 Vaccine, Influenza Vaccine, and Hepatitis B Vaccine. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Enhances vaccine efficacy using patented polysaccharide adjuvant.
Targets COVID-19 with AI-assisted development.
Addresses seasonal influenza through research efforts.
Focuses on preventing liver infections.
Funding Insights of Vaxine
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Vaxine
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Vaxine
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Vaxine Comparisons
Competitors of Vaxine
Vaxine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Emergent BioSolutions, EyeGene, Adjuvance Technologies, Kineta and Eikonoklastes, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Vaccines for viral infections are developed by the company.
|
|
| domain | founded_year | HQ Location |
Immune vaccines and diagnostics for ocular diseases are developed.
|
|
| domain | founded_year | HQ Location |
Vaccine adjuvants are designed and manufactured for medical applications.
|
|
| domain | founded_year | HQ Location |
Immune-modulating therapeutics are developed for autoimmune and infectious diseases.
|
|
| domain | founded_year | HQ Location |
Tissue factor targeting therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Immunomodulatory drugs and vaccine adjuvants targeting TLRs were developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Vaxine
Frequently Asked Questions about Vaxine
When was Vaxine founded?
Vaxine was founded in 2002.
Where is Vaxine located?
Vaxine is headquartered in Bedford Park, Australia. It is registered at Bedford Park, South Australia, Australia.
What does Vaxine do?
Vaxine was founded in 2002 in Bedford Park, Australia, within the biotechnology sector. Vaccines targeting diseases such as pneumococcus, typhoid fever, Shigella, tuberculosis, Japanese encephalitis, West Nile virus, malaria, HIV, and cancer are developed. A polysaccharide-based adjuvant platform named Advax is used to boost antibody and T-cell responses to antigens. Operations include a veterinary division where adjuvants for animal health issues are commercialized.
Who are the top competitors of Vaxine?
Vaxine's top competitors include Adjuvance Technologies, Emergent BioSolutions and Indian Immunologicals.
What products or services does Vaxine offer?
Vaxine offers Advax™ Adjuvant Platform, COVID-19 Vaccine, Influenza Vaccine, and Hepatitis B Vaccine.